# Alexander Eggermont

Source: https://onco.cc/people/alexander-eggermont/  
OnCo record `alexander-eggermont` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Surgical oncologist who led the EORTC adjuvant ipilimumab and pembrolizumab trials in melanoma.

## Summary

Alexander Eggermont is Chief Scientific Officer of the Princess Máxima Center and Professor at Utrecht, and a former President of the EORTC and Director General of Gustave Roussy. A surgical oncologist by training, he specialises in melanoma and adjuvant immunotherapy. He led the EORTC trials that tested adjuvant checkpoint blockade in stage III melanoma: EORTC 18071 of adjuvant ipilimumab and KEYNOTE-054 of adjuvant pembrolizumab, the latter reported in the New England Journal of Medicine as a placebo-controlled trial of pembrolizumab after resection. His work helped establish immunotherapy after surgery in melanoma, and his publications are listed on PubMed.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Chief Scientific Officer, Princess Máxima Center; Professor, Utrecht; former EORTC President
- Specialisms: Melanoma; Adjuvant immunotherapy; Surgical oncology

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Eggermont%20AM%5BAuthor%5D%20adjuvant%20melanoma

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Stage III melanoma (after surgery)](https://onco.cc/cancers/stage-iii-melanoma/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [EORTC](https://onco.cc/companies/curie-nki-eortc/)
- institutions: [Gustave Roussy](https://onco.cc/institutions/gustave-roussy/), [Princess Máxima Center for Pediatric Oncology](https://onco.cc/institutions/princess-maxima/)

---
JSON: https://onco.cc/api/v1/entities/alexander-eggermont.json